Is Early Loss of Minimal Luminal Diameter After Successful PTCA Prevented by c7E3 IIb/IIIa Antiplatelet Antibody?

1998 ◽  
Vol 31 (2) ◽  
pp. 55A
Author(s):  
M Leon
Keyword(s):  
Antiplatelet Antibody ◽  
Luminal Diameter ◽  
Early Loss ◽  
Minimal Luminal Diameter

Preprocedural β-Blockers in the Functional Assessment of Intermediate Coronary Lesions by Instantaneous Wave-Free Ratio

Angiology ◽  
2021 ◽  
pp. 000331972199617
Author(s):  
Monica Verdoia ◽  
Rocco Gioscia ◽  
Matteo Nardin ◽  
Orazio Viola ◽  
Marta Francesca Brancati ◽  
...  
Keyword(s):  
Functional Assessment ◽  
Lesion Length ◽  
Functional Evaluation ◽  
Luminal Diameter ◽  
Coronary Syndrome ◽  
Coronary Stenoses ◽  
Minimal Luminal Diameter ◽  
Coronary Lesions ◽  
Β Blockers ◽  
The Impact

Aim: Instantaneous wave-free ratio (iFR) has emerged as the strategy of choice for the assessment of intermediate coronary lesions. The impact of preprocedural β-blockers therapy on the iFR was the aim of this study. Methods: We included patients undergoing functional assessment of intermediate (40%-70%) coronary lesions in 2 centers. The iFR measurement was performed by pressure-recording guidewire and calculated at the core laboratory using the manufacturers’ dedicated software. Minimal luminal diameter, reference diameter, percent diameter stenosis, and length of the lesion were measured. Positive iFR was considered for values <0.90. Results: We included 197 patients undergoing functional evaluation of 223 coronary lesions. Patients on β-blockers (69%) had more frequently hypertension ( P = .05); previous myocardial infarction ( P = .01); therapy with clopidogrel ( P = .02), statins, and aspirin; and acute coronary syndrome at presentation ( P < .001, respectively). Mean iFR values were slightly higher in patients on β-blockers (0.94 ± 0.06 vs 0.92 ± 0.06, P = .11). The rate of positive iFR was significantly lower with β-blockers (14.9% vs 27.5%, P = .04). On multivariate analysis, β-blockers use was a predictor of the significance of coronary stenoses (odds ratio [OR] = 0.48; 95% CI = 0.23-0.98; P = .05) together with lesion length (OR = 1.04; 95% CI = 1.01-1.07; P = .007). Conclusion: Among patients undergoing iFR, preprocedural β-blockers are associated with higher absolute values and a lower rate of positive iFR.

Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: Prediction of restenosis on the basis of exercise capacity

2000 ◽  
Vol 139 (3) ◽  
pp. 0482-0490
Author(s):  
Bj[oslash]rn J. J[oslash]rgensen ◽  
Svein J. Simonsen ◽  
Knut J. Endresen ◽  
Kolbj[oslash]rn J. Forfang ◽  
Thore J. Egeland ◽  
...  
Keyword(s):  
Exercise Capacity ◽  
Coronary Angioplasty ◽  
Luminal Diameter ◽  
Physiologic Response ◽  
Minimal Luminal Diameter ◽  
Gain And Loss

scholarly journals 1000–38 Correlation of Minimal Luminal Diameter and the Decrease in Ischemic Response at Successive Occlusions During PTCA

1995 ◽  
Vol 25 (2) ◽  
pp. 346A
Author(s):  
Luciano Pizzulli ◽  
Markus Zirbes ◽  
Wolfgang Fehske ◽  
Andreas Hagendorff ◽  
Dietrich Pfeiffer ◽  
...  
Keyword(s):  
Luminal Diameter ◽  
Minimal Luminal Diameter

scholarly journals Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy

2000 ◽  
Vol 36 (5) ◽  
pp. 1536-1541 ◽  
Author(s):  
Manel Sabaté ◽  
Marco A Costa ◽  
Ken Kozuma ◽  
I.Patrick Kay ◽  
Connie J van der Wiel ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Clinical Implications ◽  
Luminal Diameter ◽  
Minimal Luminal Diameter

Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: Incidence and impact on angiographic late loss

2007 ◽  
Vol 69 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Marco A. Costa ◽  
Manel Sabaté ◽  
Dominick J. Angiolillo ◽  
Paula Hu ◽  
Pilar Jimenez-Quevedo ◽  
...  
Keyword(s):  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Bare Metal ◽  
Luminal Diameter ◽  
Late Loss ◽  
Drug Eluting ◽  
Minimal Luminal Diameter

Predictors of Favorable Angiographic Outcomes After Drug-Coated Balloon Use for de novo Small Vessel Coronary Disease (DCB-ONLY)

Angiology ◽  
2021 ◽  
pp. 000331972110155
Author(s):  
Woong Chol Kang ◽  
Sang Min Park ◽  
Albert Youngwoo Jang ◽  
Pyung Chun Oh ◽  
Eun-Seok Shin ◽  
...  
Keyword(s):  
De Novo ◽  
Small Vessel Disease ◽  
Vessel Diameter ◽  
Target Lesion ◽  
Small Vessel ◽  
Luminal Diameter ◽  
Minimal Luminal Diameter ◽  
Late Luminal Loss ◽  
Drug Coated Balloon

We evaluated the angiographic parameter and clinical outcomes of drug-coated balloon (DCB) to assess the optimal angiographic criteria in de novo small vessel disease (SVD). Patients (n = 424, mean age: 64.4 ± 11.2 years, men: 69.8%) at 20 sites in Korea were prospectively enrolled. The primary end point was late luminal loss (LLL) at 9-month follow-up angiography. Secondary end points included restenosis rates, target lesion failure (TLF), and DCB-related thrombosis during the 12-month follow-up period. We included 403 patients for analysis excluding 21 patients who required bailout stenting. Baseline mean reference vessel .diameter was 2.52 ± 0.39 mm and mean minimal luminal diameter (MLD) was 0.71 ± 0.40 mm. The mean MLD was 1.54 ± 0.37 mm after DCB. Late luminal loss was −0.01 ± 0.43 mm and restenosis was noted in 26 patients (12.2%). Minimal luminal diameter >1.6 mm and % diameter stenosis (DS ) <45% after DCB was associated maintenance of MLD without LLL at 9-months. Multivariate analysis demonstrated that %DS at baseline and post-MLD was associated with the restenosis. During 12-month follow-up, TLF was 2.6% including 1 cardiac death, 1 myocardial infarction, and 10 ischemia-driven target lesion revascularizations. Drug-coated balloon showed a low restenosis and lower LLL despite high in-segment DS. Post-MLD and % DS may be helpful to get optimal results in de novo SVD after DCB.

Sign in / Sign up

Export Citation Format

Share Document